$49.21
-0.87-1.74%
At Close: -
$49.21
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Apogee Therapeutics
APGENASDAQ
Apogee Therapeutics (NASDAQ:APGE) Stock, Analyst Ratings, Price Targets, Forecasts
Apogee Therapeutics Inc has a consensus price target of $70.67 based on the ratings of 7 analysts. The high is $95 issued by Stifel on March 5, 2024. The low is $40 issued by Wedbush on August 8, 2023. The 3 most-recent analyst ratings were released by B of A Securities, Jefferies, and Stifel on May 10, 2024, March 6, 2024, and March 5, 2024, respectively. With an average price target of $83.33 between B of A Securities, Jefferies, and Stifel, there's an implied 69.34% upside for Apogee Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Jefferies
Stifel
Guggenheim
BTIG
1calculated from analyst ratings
Analyst Ratings for Apogee Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/10/2024 | Buy Now | 62.57% | B of A Securities | Geoff Meacham | → $80 | Initiates | → Buy | Get Alert |
| 03/06/2024 | Buy Now | 52.41% | Jefferies | Akash Tewari | $37 → $75 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 93.05% | Stifel | Akash Tewari | $46 → $95 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 84.92% | Guggenheim | Seamus Fernandez | $44 → $91 | Maintains | Buy | Get Alert |
| 01/03/2024 | Buy Now | -10.59% | Guggenheim | Seamus Fernandez | $29 → $44 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | -12.62% | BTIG | Julian Harrison | → $43 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | — | TD Cowen | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | -18.72% | Wedbush | David Nierengarten | → $40 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | -30.91% | Stifel | Akash Tewari | → $34 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | -41.07% | Jefferies | Akash Tewari | → $29 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | -41.07% | Guggenheim | Seamus Fernandez | → $29 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Apogee Therapeutics (APGE) stock?
The latest price target for Apogee Therapeutics (NASDAQ:APGE) was reported by B of A Securities on May 10, 2024. The analyst firm set a price target for $80.00 expecting APGE to rise to within 12 months (a possible 62.57% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apogee Therapeutics (APGE)?
The latest analyst rating for Apogee Therapeutics (NASDAQ:APGE) was provided by B of A Securities, and Apogee Therapeutics initiated their buy rating.
When was the last upgrade for Apogee Therapeutics (APGE)?
There is no last upgrade for Apogee Therapeutics
When was the last downgrade for Apogee Therapeutics (APGE)?
There is no last downgrade for Apogee Therapeutics.
When is the next analyst rating going to be posted or updated for Apogee Therapeutics (APGE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apogee Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apogee Therapeutics was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.
Is the Analyst Rating Apogee Therapeutics (APGE) correct?
While ratings are subjective and will change, the latest Apogee Therapeutics (APGE) rating was a initiated with a price target of $0.00 to $80.00. The current price Apogee Therapeutics (APGE) is trading at is $49.21, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.